Table 2.
Global service coverage targets that would eliminate HBVa and HCVb as public health threats, 2015-2030.
| Target areas | Baseline 2015 | 2020 target | 2030 target | |||
| Service coverage | ||||||
| Prevention | ||||||
| Three-dose HBV for infants (coverage %) | 84 | 90 | 90 | |||
| Prevention of mother-to-child transmission of HBV: hepatitis B birth-dose vaccination or other approaches (coverage %) | 39 | 50 | 90 | |||
| Blood and injection safety | ||||||
| Blood safety: donations screened with quality assurance (coverage %) | 97 | 95 | 100 | |||
| Injection safety: use of engineered devicesc (coverage %) | 5 | 50 | 90 | |||
| Harm reduction (sterile syringe/needle set distributed per person per year for people who inject drugs [PWID]) | 20 | 200 | 300 | |||
| Treatment | ||||||
| Diagnosis of HBV and HCV (coverage %) | 9-20 | 30 | 90 | |||
| Treatment of HBV and HCV | 7%-8% | 5 million (HBV) and 3 million (HCV) | 80% eligible treated | |||
| Impact leading to elimination | ||||||
| Incidence of chronic HBV and HCV infections | 6-10 million | 30% reduction | 90% reduction | |||
| Mortality from chronic HBV and HCV infections | 1.34 million | 10% reduction | 65% reduction | |||
aHBV: hepatitis B virus.
bHCV: hepatitis C virus.
cAlthough the service coverage target is about output (adoption of reuse prevention injection devices), the C.5 indicator focuses on outcome (provision of safe injections).